Meeting
2021 ASCO Annual Meeting
Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.
Authors
Marlana Orloff
Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA
Marlana Orloff , Richard D. Carvajal , Alexander Noor Shoushtari , Joseph J. Sacco , Max Schlaak , Claire Watkins , Shaad Essa Abdullah , Howard Goodall , Marcus O. Butler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03070392
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 9526)
DOI
10.1200/JCO.2021.39.15_suppl.9526
Abstract #
9526
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).
First Author: Richard D. Carvajal
Poster
2023 ASCO Annual Meeting
A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).
First Author: Diwakar Davar
Poster
2022 ASCO Annual Meeting
Analysis of the effect of systemic corticosteroids on survival from tebentafusp in a phase 3 trial of metastatic uveal melanoma.
First Author: Alexandra Ikeguchi
Poster
2021 ASCO Annual Meeting
Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.
First Author: Jessica Cecile Hassel